Neurent Medical
Neurent Medical offers the NEUROMARK System, a minimally invasive in-office procedure that treats chronic rhinitis by using low-power radiofrequency energy to disrupt overactive posterior nasal nerves. The FDA-cleared system features impedance-controlled technology for precise, multi-point nerve targeting, with clinical data showing durable symptom improvement at one year. The treatment is designed for ENT physicians seeking a durable alternative to ongoing symptom management.
- Medical Devices
- Healthcare Technology
- Hardware
Funding
Raised to date
$93.1MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 2 rounds
ABEIELFH+1€62.5M · Series C
Announced Feb 2026 · from article date
Disclosed cumulative: $93.1M
Founders
Founder details are not available yet.
Product
Problem
Chronic rhinitis affects approximately 25% of American adults, causing persistent symptoms that adversely impact sleep, cognitive function, and overall quality of life. Existing treatments often focus on symptom management rather than addressing the underlying nerve activity that drives the condition, leaving many patients without durable relief.
Solution
Neurent Medical provides the NEUROMARK System, a clinically proven, minimally invasive procedure that targets the root cause of chronic rhinitis by disrupting overactive posterior nasal nerves using low-power radiofrequency energy. The procedure is performed in an ENT office setting, typically requires no downtime, and allows patients to return to their regular day immediately. Clinical evidence demonstrates durable symptom improvement, with participants achieving clinically meaningful differences in Total Nasal Symptom Scores one year after treatment. The system's proprietary design and advanced algorithmic control enable physicians to precisely target and safely disrupt multiple underlying nerve branches in a single procedure.
Target Audience
Primary customers are ear, nose, and throat (ENT) physicians and otorhinolaryngology practices seeking an in-office, durable treatment option for patients suffering from chronic rhinitis.
Features
- Multi-point nerve disruption therapy using low-power radiofrequency energy to safely ablate posterior nasal nerves
- Proprietary Impedance Controlled Radiofrequency technology providing real-time feedback for greater treatment confidence, control, and predictability
- Advanced algorithmic control enabling precise targeting of multiple nerve branches in a single procedure
- Minimally invasive in-office procedure with no downtime for patients
- FDA 510(k) clearance and Category I CPT code (31242) for endoscopic destruction of the posterior nasal nerve
- Clinically validated with 1-year outcomes showing durable symptom relief